ABSTRACT The PD-1/PD-L1 axis is characterized as an important checkpoint of immune
activation, particularly through negatively regulating T cell function. Although accumulated …

Immunotherapy has recently become a new focus for the treatment of malignant tumors
following the surgery, chemotherapy, radiotherapy, and molecular targeted therapy …

AG declares the following potential conflicts of interest, outside the submitted paper: grants,
personal fees and non-financial support from Roche, Novartis, Eisai; personal fees and …

Significant technological advances in radiotherapy have been made in the past few
decades. High-precision radiotherapy has recently become popular and is contributing to …

Introduction Immune escape frequently occurs and restricts the durability of the antitumor
immune response to radiotherapy. Programmed death 1 (PD-1) and programmed death …

We report the case of a 61-year-old man with squamous cell carcinoma of the left lung and
mediastinal lymph node metastases who received nivolumab and experienced a better …

Background Manipulation of immune checkpoints such as CTLA4 or PD-1 with targeted
antibodies has recently emerged as an effective anticancer strategy in multiple …

11047 Background: Sarcomas are a heterogeneous group of diseases in need of more
effective treatments. Different subtypes of soft tissue and bone sarcomas have been shown …

Nivolumab, a programmed death 1 (PD-1) immune checkpoint inhibitor antibody, has been
approved in the second-line treatment of metastatic squamous NSCLC. 1 However, only a …

Tumor relapse after radiotherapy may be due to the upregulation of programmed cell death
ligand 1 (PD-L1). We demonstrated that anti-PD-L1 antibody synergizes with radiation to …